REMINISIN are indicated for the symptomatic treatment of: Mild, moderately severe and severe dementia of the Alzheimer's type; Vascular dementia (dementia associated with cerebrovascular disease); Dementia with Lewy bodies (DLB).
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
